Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.53 |
| ▸ | ANPEP | P15144 | 4/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402062 | 1.00 | MMP2 (0.53) | MMP2ANPEPAGTR2ALDH1A1LMNA | |
| SCHEMBL4970511 | 1.00 | MMP2 (0.53) | MMP2ANPEPAGTR2ALDH1A1LMNA | |
| SCHEMBL12267670 | 0.90 | MMP2 (0.67) | MMP2ANPEPMEN1KMT2AMMP3 | |
| SCHEMBL5009471 | 0.90 | MMP2 (0.52) | MMP2ANPEPAGTR2ALDH1A1LMNA | |
| SCHEMBL2400737 | 0.90 | MMP2 (0.52) | MMP2ANPEPAGTR2ALDH1A1LMNA | |
| SCHEMBL2398912 | 0.88 | MMP2 (0.50) | MMP2ANPEPAGTR2ACE | |
| SCHEMBL2404098 | 0.88 | MMP2 (0.49) | MMP2ANPEPAGTR2ALDH1A1LMNA | |
| SCHEMBL2399790 | 0.86 | MMP2 (0.57) | MMP2ANPEPAGTR2ACEHPGD | |
| SCHEMBL2526009 | 0.86 | MMP2 (0.57) | MMP2ANPEPAGTR2ACEHPGD | |
| SCHEMBL2401942 | 0.84 | MMP2 (0.58) | MMP2ANPEPAGTR2ACEHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622496-B2 | antiarrhythmia agents; 1-(2-Amino-acetyl)-4-(benzoylamino)-pyrrolidine-2-carboxylic acid; desirable bioavailability properties | ZEALAND PHARMA A/S (DK) | 2009-11-24 | — | — | US | disclosed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149460-A1 | Modified lysine-mimetic compounds | MYLK2, KCNN2, KCNN1 | MMP2 1902/4885ANPEP 491/4885AGTR2 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.